ロード中...
Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications
Lopinavir-ritonavir combination is being used for the treatment of SARS-CoV-2 infection. A low dose of ritonavir is added to other protease inhibitors to take advantage of potent inhibition of cytochrome (CYP) P450 3A4, thereby significantly increasing the plasma concentration of coadministered lopi...
保存先:
| 出版年: | Cardiovasc Drugs Ther |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer US
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7486594/ https://ncbi.nlm.nih.gov/pubmed/32918656 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10557-020-07070-1 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|